US Patent Issued to LUDWIG INSTITUTE FOR CANCER RESEARCH, CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS on Dec. 23 for "Humanized and variant TGF-Beta1 specific antibodies and methods and uses thereof" (American, Swiss Inventors)

ALEXANDRIA, Va., Dec. 23 -- United States Patent no. 12,503,504, issued on Dec. 23, was assigned to LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (Zurich) and CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (Lausanne, Switzerland).

"Humanized and variant TGF-Beta1 specific antibodies and methods and uses thereof" was invented by Gerd Ritter (New York) and Steven Dunn (Epalinges, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "Antibodies, particularly humanized and variant antibodies and fragments thereof, which bind to TGF-Beta1 are provided, recognizing human and mouse TGF-Beta1, particularly that preferentially bind TGF-Beta1, including which do not recognize or bind TGF-Beta2 or TGF-Beta3. Humanized and v...